Linoleic acid-based pH-sensitive 5-ASA nanocubosome pellets for colon targeting in ulcerative colitis: in vitro and in vivo comparison with non-pH-sensitive and conventional formulations.

What To Know

This paper reports design and testing of pH-sensitive pellets that encapsulate 5-aminosalicylic acid (5‑ASA, mesalamine) in glyceryl monooleate/linoleic-acid liquid crystal nanoparticles to target drug release to the colon for ulcerative colitis treatment.

The authors describe preparation, in vitro release at acidic and near-neutral pH, pellet manufacture by extrusion–spheronisation, and characterization (FTIR, DSC, microscopy), followed by testing in a rat model of ulcerative colitis where the pH‑sensitive pellets produced the largest improvement in colon damage scores among formulations tested.

The study is presented as an abstract/summary from the journal and appears to cover both lab (in vitro) and animal (in vivo rat) experiments rather than human clinical trials.

The reported 5.7‑fold higher release at pH 6.8 versus pH 1.2 is used to support colon-targeting potential, and the authors attribute this to pH‑triggered phase changes of linoleic acid and electrostatic effects between the ionized drug and carrier.

If you are a patient: this is preclinical research showing a promising delivery system for mesalamine that could improve colon targeting, but it is not evidence that it is safe or effective in people yet.

If you are a clinician or researcher: the formulation approach and in vivo rat results may be of interest for further preclinical development or formulation studies.